MONARCH 1 was a single-arm phase II study of single-agent abemaciclib in 132 women with HER2-negative hormone receptor–positive, advanced breast cancer that had progressed on at least one line of previous endocrine therapy and at least two lines of previous chemotherapy.
The study population was heavily pretreated, and most participants had visceral disease.
Patients who had previous CDK inhibitors were excluded.
The primary end point was investigator-assessed objective response rate.The objective response rate was 19.7% at 12 months (95% CI, 13.3%–27.5%).The clinical benefit rate was 42.4%.Median PFS was 6.0 months (95% CI, 4.2–7.5).The most common adverse event was diarrhea, which occurred in 90.2% of the participants.